Dopamine agonists in Parkinson's disease: a look at apomorphine - PubMed (original) (raw)

Review

Dopamine agonists in Parkinson's disease: a look at apomorphine

A J Lees. Fundam Clin Pharmacol. 1993.

Abstract

Apomorphine is a D1 and D2 dopamine receptor agonist with anti-parkinsonian properties qualitatively similar to those seen with L-dopa. It was first used in the treatment of Parkinson's disease by Schwab in the 1950s but owing to its short duration of action, the need for parenteral administration, and adverse reactions including nausea, vomiting, postural hypotension and sedation, it was not widely prescribed. In the early 1970s, Cotzias confirmed its potent anti-parkinsonian effects and that some of its secondary effects were diametrically opposite to those seen with L-dopa. The advent of peripheral dopamine receptor antagonist drugs, which counteract the unwanted effects of apomorphine, and the development of new drug delivery systems including insulin pens and ambulatory mini pumps have led to the resurrection of apomorphine for the treatment of Parkinson's disease. Over the last five years in Europe, the drug has proved to be a major advance in the treatment of refractory "on-off" oscillations in Parkinson's disease. It has also been used as a diagnostic test for dopaminergic responsiveness in Parkinson syndromes and tremors of uncertain aetiology. The drug has also proved particularly useful in dealing with certain "off-period" disabilities, including pain, bladder dysfunction, dystonia and gastro-intestinal symptoms. Continuous steady state infusion of apomorphine by mini-pump may reduce the severity of "on" phase dyskinesias over time. The drug has also proved useful in the clinical pharmacological investigation of the pathophysiology of the motor response to dopaminergic drugs in Parkinson's disease and the occurrence of involuntary movement sequences. Neuropsychiatric side-effects are relatively infrequent when compared with ergolene dopamine agonists.(ABSTRACT TRUNCATED AT 250 WORDS)

PubMed Disclaimer

Cited by

Dopamine agonists and analogues have an antiproliferative effect on CHO-K1 cells.
Maggio R, Armogida M, Scarselli M, Salvadori F, Longoni B, Pardini C, Chiarenza A, Chiacchio S, Vaglini F, Bernardini R, Colzi A, Corsini GU. Maggio R, et al. Neurotox Res. 2000 Apr;1(4):285-97. doi: 10.1007/BF03033258. Neurotox Res. 2000. PMID: 12835096
Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma?
Dépatie L, Lal S. Dépatie L, et al. J Psychiatry Neurosci. 2001 May;26(3):203-20. J Psychiatry Neurosci. 2001. PMID: 11394190 Free PMC article. Review.
Ankk1 Loss of Function Disrupts Dopaminergic Pathways in Zebrafish.
Leggieri A, García-González J, Torres-Perez JV, Havelange W, Hosseinian S, Mech AM, Keatinge M, Busch-Nentwich EM, Brennan CH. Leggieri A, et al. Front Neurosci. 2022 Feb 8;16:794653. doi: 10.3389/fnins.2022.794653. eCollection 2022. Front Neurosci. 2022. PMID: 35210987 Free PMC article.
Neuroprotective effects of Bacopa monnieri in experimental model of dementia.
Saini N, Singh D, Sandhir R. Saini N, et al. Neurochem Res. 2012 Sep;37(9):1928-37. doi: 10.1007/s11064-012-0811-4. Epub 2012 Jun 15. Neurochem Res. 2012. PMID: 22700087
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.
Duty S, Jenner P. Duty S, et al. Br J Pharmacol. 2011 Oct;164(4):1357-91. doi: 10.1111/j.1476-5381.2011.01426.x. Br J Pharmacol. 2011. PMID: 21486284 Free PMC article. Review.

Dopamine agonists in Parkinson's disease: a look at apomorphine - PubMed (original) (raw)